Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...
REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Zacks Investment Research on MSN
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Regeneron (REGN) came out with quarterly earnings of $11.83 per share, beating the Zacks Consensus Estimate of $9.44 per share. This compares to earnings of $12.46 per share a year ago. These figures ...
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
StockStory.org on MSN
Regeneron Earnings: What To Look For From REGN
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you ...
StockStory.org on MSN
Why Are Regeneron (REGN) Shares Soaring Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter ...
The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings ... but a powerful factor that might influence its near-term stock price is how the actual results compare to these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback